# Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

> **NCT02073526** · — · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 1230 (actual)

## Conditions studied

- Inflammatory Bowel Disease
- Crohn's Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** Infliximab, adalimumab, certolizumab pegol

## Key facts

- **NCT ID:** NCT02073526
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-05
- **Final completion:** 2016-11
- **Target enrollment:** 1230 (ACTUAL)
- **Last updated:** 2016-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073526, "Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02073526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*